DBV Technologies (NASDAQ:DBVT) Stock Price Up 8.1% – Should You Buy?

DBV Technologies S.A. (NASDAQ:DBVT) rose 8.1% during mid-day trading on Tuesday . The company traded as high as $16.70 and last traded at $16.8730. 163,793 shares were traded during trading, a decline of 45% from the average daily volume of 296,862 shares. The stock had previously closed at $15.61.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. HC Wainwright restated a “buy” rating on shares of DBV Technologies in a research report on Tuesday, June 30th. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research note on Friday, May 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of DBV Technologies in a research note on Monday, June 29th. Guggenheim reissued a “buy” rating and set a $51.00 price target on shares of DBV Technologies in a research report on Monday, May 4th. Finally, Citizens Jmp increased their price objective on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, DBV Technologies presently has an average rating of “Moderate Buy” and a consensus target price of $48.50.

DBV Technologies Stock Up 8.1%

The stock has a market capitalization of $999.05 million, a PE ratio of -3.76 and a beta of -0.95. The stock has a fifty day moving average of $17.89 and a 200-day moving average of $19.75.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). DBV Technologies had a negative return on equity of 129.88% and a negative net margin of 2,895.37%.The firm had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $1.11 million. Equities research analysts expect that DBV Technologies S.A. will post -0.38 EPS for the current year.

Institutional Investors Weigh In On DBV Technologies

A number of large investors have recently added to or reduced their stakes in DBVT. Allworth Financial LP acquired a new stake in shares of DBV Technologies during the fourth quarter valued at about $32,000. Royal Bank of Canada bought a new stake in shares of DBV Technologies during the 4th quarter valued at about $34,000. GAMMA Investing LLC raised its position in shares of DBV Technologies by 38.4% during the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after purchasing an additional 744 shares during the period. Truvestments Capital LLC lifted its stake in DBV Technologies by 71.3% in the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after buying an additional 1,620 shares during the last quarter. Finally, Persistent Asset Partners Ltd acquired a new position in DBV Technologies during the 4th quarter valued at about $115,000. 71.74% of the stock is owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.